Quotient Limited Announces Achievement of Major MosaiQ™ Project Milestones and Preliminary Fiscal Fourth Quarter 2016 Financial Results
13 avr. 2016 16h05 HE
|
Quotient Limited
Initial Manufacturing System for MosaiQ™ Consumables Successfully CommissionedFirst MosaiQ™ Field Trial Instruments Built and Received for Internal Evaluation JERSEY, Channel Islands, April 13,...
Quotient Limited Announces Positive Serological Disease Screening Results and Provides MosaiQ™ Development Program Update
11 janv. 2016 07h01 HE
|
Quotient Limited
JERSEY, Channel Islands, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, will present the following update on the MosaiQ™ development...
Quotient Limited to Expand Capability of Its MosaiQ™ Next-Generation Transfusion Diagnostics Platform to Include Nucleic Acid Testing
11 janv. 2016 07h00 HE
|
Quotient Limited
Initial feasibility study demonstrates ability to detect nucleic acid using MosaiQTMPotential for a single unified platform to perform blood grouping along with serological and molecular disease...
Quotient Limited to Participate in J.P. Morgan 2016 Healthcare Conference
22 déc. 2015 14h00 HE
|
Quotient Limited
JERSEY, Channel Islands, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company’s Chairman and Chief Executive...